HUTCHMED (China) (NasdaqGS:HCM) Update / Briefing October 31, 2025 08:00 AM ET Speaker0Hello, everyone. Good evening and good morning. Thank you for joining the HUTCHMED 2025 R&D Day event. For your reference, you can go to our website to download today's presentation slides. The performance and results of operations of the HUTCHMED group contained within this presentation are historical in nature, and the past performance is no guarantee of future results. As usual, we will have a Q&A session at the end wh ...

Accessibility StatementSkip Navigation SALT LAKE CITY, Oct. 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2025 financial results on Thursday, November 13, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Manage ...

https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=174682&wire=4 MLTX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) It's sole drug candidate, SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL- 17A and IL-17F); (2) SLK's distinct Nanobody structure would not confer a superior clinical benefit ...

中新社香港10月31日电 (记者 戴小橦)10月31日，来到10月最后一个交易日，港股市场呈现调整态势， 三大指数同步走弱。而纵观整个10月，港股IPO市场热度持续高企，单月有超过10家公司成功登陆香港 交易及结算所有限公司(简称"港交所")，市场结构性分化特征愈发鲜明。 银河证券发布研究报告指出，医药板块近期已呈现显著结构性修复趋势。当前二级市场行情回暖驱动一 级市场投融资回升，医疗器械招投标数据已有好转，以旧换新积压需求逐步释放。 方正证券发布的研究报告表示，医药行业景气度正步入新一轮上行周期。行业"出海"订单加速释放，且 整体尚处于成长早期，向上动能强劲。报告看好"出海"能力突出的生物品类上游公司，相信创新药"出 海"将迎来机遇。 招商证券发布研报称，美联储降息促使美国与新兴市场利差收窄、美元走弱，从而吸引国际资金流入香 港等新兴市场，港股中长期有望呈现渐进式上涨。与此同时，美联储降息周期亦有望改善创新药领域的 融资环境，推动研发进展。 31日，港股三大指数齐跌，香港恒生指数跌1.43%，恒生科技指数跌2.37%，国企指数跌1.91%。(完) 10月31日，香港恒生指数收市报25906.65点，下跌37 ...

TRENDING: Palantir, Robinhood Earnings Due After Market's Tricky October IBD Videos Get market updates, educational videos, webinars, and stock analysis. 11/01/2025Three S&P 500 components, including JPMorgan Chase and Eli Lilly, are among five stocks near buy points. 11/01/2025Three S&P 500 components, including JPMorgan Chase and Eli Lilly,... INVESTING RESOURCES Take a Trial Today Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only ...

NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and certain of its assets related to HOOKIPA’s HB-500 program to Gilead Sciences, Inc. (“Gilead”). In connection with the consideration and evaluation of HOOKIPA’s long-term prospects and strategies by HOOKIPA’s board of directors, on May 21, 2025 HOOKIPA entered into an asset purchase agreement (“Asset Purchase Agree ...

Core Insights - Clearmind Medicine Inc. has announced a U.S. patent application for its non-hallucinogenic compound MEAI, aimed at treating cocaine addiction, enhancing its intellectual property portfolio [1][2][4] - Cocaine use disorder is a significant global health issue with no FDA-approved treatments, presenting a market opportunity projected to grow from $1.36 billion in 2025 to $2.03 billion by 2032 [2] - MEAI is designed to modulate serotonin and dopamine pathways, potentially offering a safer alternative to existing behavioral interventions for addiction [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics for under-treated health problems, including addiction [1][4] - The company currently holds nineteen patent families with 31 granted patents and plans to pursue additional patents to strengthen its intellectual property [5] Market Context - The global market for cocaine addiction treatment is experiencing urgent demand for new solutions, highlighting the potential impact of Clearmind's developments in this area [2][3]

Core Insights - Zai Lab Limited will participate in two investor conferences in November and December 2025, including the Jefferies Global Healthcare Conference and Citi's 2025 Global Healthcare Conference [1] Company Overview - Zai Lab Limited is a research-based, commercial-stage biopharmaceutical company operating in China and the United States, focusing on innovative products in oncology, immunology, neuroscience, and infectious diseases [2] Upcoming Events - The Jefferies Global Healthcare Conference will take place on November 19, 2025, at 8:30 AM GMT in London, and the Citi's 2025 Global Healthcare Conference will occur on December 2, 2025, at 1:00 PM ET in Miami, Florida [1] - Live webcasts of these events will be available on Zai Lab's Investor Relations page, with archived replays accessible for up to 90 days [1] Financial Reporting - Zai Lab is set to announce its third quarter 2025 financial results and recent corporate updates on November 6, 2025, before the U.S. equity markets open [6]

Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA Patients randomized to either 10 or 20 mg/kg of muzastotug, in combination with KEYTRUDA with up to 30 patients per arm Company anticipates trial completion in early 2027, and potential updates in 2026 Additional updates from the ongoing Phase 1b/2 trial with muzastotug, previously reported at ASCO 2025, are anticipated in the coming months SAN DIEGO and SUZHOU, China, ...

WALTHAM, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in November: 2025 Truist Securities BioPharma Symposium, New York, NYThursday, November 6, 2025, Panel - 8:10 a.m. ETStifel 2025 Healthcare Confere ...